|
|
|
|
|
|
Companies > Preclinical
|
|
|
Cell Targeting (acquired by BioTime) is developing a family of novel homing peptides to enhance targeting of therapeutic cells to specific tissues or organs. The company’s technology has both clinical and research applications with a portfolio of 15 target organs and tissues.
Funders:
Toucan Ventures, DARPA
|
|
|
|
|